Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

Signal Transduction and Targeted Therapy 2026 Open access

Read full text
Authors: Linong Ji, Leili Gao, Junhang Tian, RUIHUA DONG, Zhongtao Zhang, Hongyan Shu, Jing Zhao, Liyuan Zhao, Anshun He, Tian Xie, Yue Li, Wei Chen
DOI: 10.1038/s41392-026-02586-8
Cited by: 3
References: 30

Abstract

Abstract Bofanglutide is a novel biweekly (once every two weeks; Q2W) glucagon-like peptide-1 receptor agonist. We evaluated the efficacy and safety of bofanglutide in Chinese adults with overweight or obesity in a randomized, double-blind, placebo-controlled phase 2b trial (ClinicalTrials.gov, NCT06256562). Adults with overweight (body mass index [BMI] ≥24,

Fields of Study & Subjects

Diabetes Treatment and Management Bariatric Surgery and Outcomes Pancreatic function and diabetes

Publication details

Journal / source
Signal Transduction and Targeted Therapy
Publisher
Springer Science and Business Media LLC
Volume
11
Issue
1
Publication date
27 February 2026
Language
EN